Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Public ClinicalTrials.gov record NCT06136624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.
Study identification
- NCT ID
- NCT06136624
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,310 participants
Conditions and interventions
Conditions
Interventions
- Opevesostat Drug
- Abiraterone acetate Drug
- Enzalutamide Drug
- Hydrocortisone Drug
- Fludrocortisone acetate Drug
- Prednisone Drug
- Dexamethasone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 30, 2023
- Primary completion
- Aug 1, 2028
- Completion
- Feb 14, 2030
- Last update posted
- Aug 27, 2026
2023 – 2030
United States locations
- U.S. sites
- 48
- U.S. states
- 27
- U.S. cities
- 44
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) | Orange | California | 92868 | Completed |
| Stanford Cancer Center ( Site 0036) | Palo Alto | California | 94304 | Recruiting |
| Kaiser Permanente Riverside Medical Center ( Site 0099) | Riverside | California | 92505 | Recruiting |
| Anschutz Cancer Pavilion ( Site 0046) | Aurora | Colorado | 80045 | Recruiting |
| University of Colorado Health - Highlands Ranch Hospital ( Site 0111) | Highlands Ranch | Colorado | 80129 | Recruiting |
| Colorado Clinical Research ( Site 0067) | Lakewood | Colorado | 80228 | Completed |
| University of Colorado Health - Lone Tree Medical Center ( Site 0112) | Lone Tree | Colorado | 80124 | Recruiting |
| Yale-New Haven Hospital-Yale Cancer Center ( Site 0064) | New Haven | Connecticut | 06510 | Recruiting |
| Florida Cancer Specialists - South ( Site 7003) | Fort Myers | Florida | 33901 | Completed |
| Bruce W. Carter Veterans Affairs Medical Center ( Site 0082) | Miami | Florida | 33125 | Completed |
| University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051) | Miami | Florida | 33136 | Recruiting |
| University of Illinois at Chicago ( Site 0105) | Chicago | Illinois | 60612 | Recruiting |
| University of Chicago Medical Center ( Site 0045) | Chicago | Illinois | 60637 | Recruiting |
| University of Iowa ( Site 0047) | Iowa City | Iowa | 52242 | Completed |
| University of Kentucky Chandler Medical Center ( Site 0048) | Lexington | Kentucky | 40536 | Completed |
| Ochsner Clinic Foundation ( Site 0108) | New Orleans | Louisiana | 70121 | Completed |
| Baltimore Veterans Affairs Medical Center ( Site 0069) | Baltimore | Maryland | 21201 | Recruiting |
| Greenebaum Comprehensive Cancer Center ( Site 0049) | Baltimore | Maryland | 21201 | Recruiting |
| Henry Ford Hospital ( Site 0015) | Detroit | Michigan | 48202 | Completed |
| Avera Cancer Institute - Marshall ( Site 0122) | Marshall | Minnesota | 56258 | Recruiting |
| M Health Fairview Clinics and Surgery Center ( Site 0019) | Minneapolis | Minnesota | 55455 | Recruiting |
| Metro-Minnesota Community Clinical Oncology ( Site 0014) | Saint Louis Park | Minnesota | 55416 | Active, not recruiting |
| Hattiesburg Clinic Hematology/Oncology ( Site 0120) | Hattiesburg | Mississippi | 39401 | Recruiting |
| Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062) | St Louis | Missouri | 63110 | Recruiting |
| University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095) | Omaha | Nebraska | 68105 | Recruiting |
| Comprehensive Cancer Centers of Nevada ( Site 0010) | Las Vegas | Nevada | 89148 | Recruiting |
| Atlantic Health System Morristown Medical Center ( Site 0115) | Morristown | New Jersey | 07960 | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 0033) | New Brunswick | New Jersey | 08903 | Completed |
| James J. Peters VA Medical Center ( Site 0088) | The Bronx | New York | 10468 | Recruiting |
| University Hospitals Cleveland Medical Center ( Site 0043) | Cleveland | Ohio | 44106 | Recruiting |
| Oregon Health and Science University ( Site 0028) | Portland | Oregon | 97239 | Completed |
| VA Portland Health Care System ( Site 0058) | Portland | Oregon | 97239 | Recruiting |
| AHN Allegheny General Hospital ( Site 0001) | Pittsburgh | Pennsylvania | 15212 | Completed |
| Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) | Charleston | South Carolina | 29401 | Completed |
| Avera Cancer Institute - Aberdeen ( Site 0123) | Aberdeen | South Dakota | 57401 | Recruiting |
| Avera Cancer Institute - Mitchell ( Site 0121) | Mitchell | South Dakota | 57301 | Recruiting |
| Avera Cancer Institute - Pierre ( Site 0118) | Pierre | South Dakota | 57501 | Recruiting |
| Avera Cancer Institute- Research ( Site 0094) | Sioux Falls | South Dakota | 57105 | Recruiting |
| Avera Cancer Institute - Yankton ( Site 0117) | Yankton | South Dakota | 57078 | Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Central/South Texas ( Site 8003) | Austin | Texas | 78731 | Recruiting |
| Texas Oncology - DFW ( Site 8001) | Dallas | Texas | 75246 | Completed |
| Texas Oncology - Gulf Coast ( Site 8002) | Houston | Texas | 77024 | Recruiting |
| University of Virginia Health System ( Site 0054) | Charlottesville | Virginia | 22908 | Recruiting |
| VCU Health Adult Outpatient Pavillion ( Site 0061) | Richmond | Virginia | 23219 | Completed |
| Blue Ridge Cancer Care ( Site 0004) | Roanoke | Virginia | 24014 | Recruiting |
| Fred Hutchinson Cancer Center ( Site 0013) | Seattle | Washington | 98109 | Recruiting |
| Medical College of Wisconsin ( Site 0020) | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 240 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06136624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06136624 live on ClinicalTrials.gov.